HC Wainwright & Co. Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained its Buy rating on Cartesian Therapeutics (NASDAQ:RNAC) but lowered the price target from $49 to $45.
August 12, 2024 | 9:58 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained its Buy rating on Cartesian Therapeutics but lowered the price target from $49 to $45.
The maintained Buy rating suggests continued confidence in Cartesian Therapeutics' prospects, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100